Axial Spondyloarthritis
Axial spondyloarthritis can be ‘reliably diagnosed’ shortly after chronic back pain onset
Most patients with recent-onset chronic back pain suspected of axial spondyloarthritis can be “unequivocally and reliably diagnosed” at their first rheumatology visit, according to data published in the Annals of the Rheumatic Diseases.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis
SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.
Ixekizumab reduces erosion, increases backfill scores in radiographic axial SpA
SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.
Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks
Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.
Taking ‘shots on goal’: The continuing fight to bring precision medicine to rheumatology
Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.
Patients with axial spondyloarthritis exhibit shared microbiome dysbiosis
Patients with axial spondyloarthritis and other related inflammatory diseases demonstrate common microbiome dysfunction characteristics, according to data published in Arthritis & Rheumatology.
Early axial spondyloarthritis defined as a symptom duration of less than 2 years
A new consensus definition for early axial spondyloarthritis indicates disease that has manifested symptoms for less than 2 years, according to a recommendation published in Annals of the Rheumatic Diseases.
Patients with undiagnosed psoriatic arthritis, axial SpA often ‘bounced’ around providers
Patients with axial spondyloarthritis and psoriatic arthritis routinely “bounce” from one provider to the next for years before finally receiving the correct diagnosis in a rheumatology clinic, according to experts.
Rheumatology patients with anxiety, depression demonstrate low self-management
Patients with anxiety or depression are less likely to exhibit healthy self-management for their rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis, according to data presented at EULAR 2023 Congress.